Dry Panels Supporting External Quality Assessment Programs for Next Generation Sequencing-Based HIV Drug Resistance Testing

被引:2
|
作者
Noguera-Julian, Marc [1 ,2 ]
Lee, Emma R. [3 ]
Shafer, Robert W. [4 ]
Kantor, Rami [5 ]
Ji, Hezhao [3 ,6 ]
机构
[1] Hosp Badalona Germans Trias & Pujol, IrsiCaixa AIDS Res Inst, Badalona 08196, Spain
[2] Univ Vic, Cent Univ Catalonia, Fac Med, Chair AIDS & Related Illnesses,Ctr Hlth & Social, Ctra Roda 70, Vic 08500, Spain
[3] Publ Hlth Agcy Canada, Natl Microbiol Lab, JC Wilt Infect Dis Res Ctr, Natl HIV & Retrovirol Labs, Winnipeg, MB R3E 3R2, Canada
[4] Stanford Univ, Med Sch, Stanford, CA 94305 USA
[5] Brown Univ, Div Infect Dis, Alpert Med Sch, Providence, RI 02903 USA
[6] Univ Manitoba, Rady Fac Hlth Sci, Dept Med Microbiol & Infect Dis, Winnipeg, MB R3E 0J9, Canada
来源
VIRUSES-BASEL | 2020年 / 12卷 / 06期
关键词
HIV; drug resistance testing; next generation sequencing; external quality assessment; dry panel; MUTATIONS;
D O I
10.3390/v12060666
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
External quality assessment (EQA) is a keystone element in the validation and implementation of next generation sequencing (NGS)-based HIV drug resistance testing (DRT). Software validation and evaluation is a critical element in NGS EQA programs. While the development, sharing, and adoption of wet lab protocols is coupled with the increasing access to NGS technology worldwide, rendering it easy to produce NGS data for HIV-DRT, bioinformatic data analysis remains a bottleneck for most of the diagnostic laboratories. Several computational tools have been made available, via free or commercial sources, to automate the conversion of raw NGS data into an actionable clinical report. Although different software platforms yield equivalent results when identical raw NGS datasets are analyzed for variations at higher abundance, discrepancies arise when variations at lower frequencies are considered. This implies that validation and performance assessment of the bioinformatics tools applied in NGS HIV-DRT is critical, and the origins of the observed discrepancies should be determined. Well-characterized reference NGS datasets with ground truth on the genotype composition at all examined loci and the exact frequencies of HIV variations they may harbor, so-called dry panels, would be essential in such cases. The strategic design and construction of such panels are challenging but imperative tasks in support of EQA programs for NGS-based HIV-DRT and the validation of relevant bioinformatics tools. Here, we present criteria that can guide the design of such dry panels, which were discussed in the Second International Winnipeg Symposium themed for EQA strategies for NGS HIVDR assays.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] External Quality Assessment for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Unique Requirements and Challenges
    Lee, Emma R.
    Gao, Feng
    Sandstrom, Paul
    Ji, Hezhao
    VIRUSES-BASEL, 2020, 12 (05):
  • [2] External Quality Assessment Program for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Logistical Considerations
    Ji, Hezhao
    Parkin, Neil
    Gao, Feng
    Denny, Thomas
    Jennings, Cheryl
    Sandstrom, Paul
    Kantor, Rami
    VIRUSES-BASEL, 2020, 12 (05):
  • [3] Development and Application of Performance Assessment Criteria for Next-Generation Sequencing-Based HIV Drug Resistance Assays
    Becker, Michael G.
    Liang, Dun
    Cooper, Breanna
    Le, Yan
    Taylor, Tracy
    Lee, Emma R.
    Wu, Sutan
    Sandstrom, Paul
    Ji, Hezhao
    VIRUSES-BASEL, 2020, 12 (06):
  • [4] National external quality assessment for next-generation sequencing-based diagnostics of primary immunodeficiencies
    Kim Elsink
    Manon M. H. Huibers
    Iris H. I. M. Hollink
    Lars T. van der Veken
    Robert F. Ernst
    Annet Simons
    Evelien Zonneveld-Huijssoon
    Annemieke H. van der Hout
    Kristin M. Abbott
    Alexander Hoischen
    Marc Pieterse
    Taco W. Kuijpers
    Joris M. van Montfrans
    Mariëlle E. van Gijn
    European Journal of Human Genetics, 2021, 29 : 20 - 28
  • [5] National external quality assessment for next-generation sequencing-based diagnostics of primary immunodeficiencies
    Elsink, Kim
    Huibers, Manon M. H.
    Hollink, Iris H. I. M.
    van der Veken, Lars T.
    Ernst, Robert F.
    Simons, Annet
    Zonneveld-Huijssoon, Evelien
    van der Hout, Annemieke H.
    Abbott, Kristin M.
    Hoischen, Alexander
    Pieterse, Marc
    Kuijpers, Taco W.
    van Montfrans, Joris M.
    van Gijn, Marielle E.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2021, 29 (01) : 20 - 28
  • [6] Bioinformatic data processing pipelines in support of next-generation sequencing-based HIV drug resistance testing: the Winnipeg Consensus
    Ji, Hezhao
    Enns, Eric
    Brumme, Chanson J.
    Parkin, Neil
    Howison, Mark
    Lee, Emma R.
    Capina, Rupert
    Marinier, Eric
    Avila-Rios, Santiago
    Sandstrom, Paul
    Van Domselaar, Gary
    Harrigan, Richard
    Paredes, Roger
    Kantor, Rami
    Noguera-Julian, Marc
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 (10)
  • [7] Performance of Next Generation Sequencing-Based Gene Panels for Primary Immunodeficiencies
    Coonrod, Emily M.
    Durtschi, Jacob
    Hill, Harry R.
    Voelkerding, Karl V.
    Kumanovics, Attila
    JOURNAL OF CLINICAL IMMUNOLOGY, 2014, 34 (03) : 385 - 385
  • [8] Minimizing Next-Generation Sequencing Errors for HIV Drug Resistance Testing
    Fernandez-Caballero, Jose A.
    Chueca, Natalia
    Poveda, Eva
    Garcia, Federico
    AIDS REVIEWS, 2017, 19 (04) : 231 - 238
  • [9] Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework
    Capina, Rupert
    Li, Katherine
    Kearney, Levon
    Vandamme, Anne-Mieke
    Harrigan, P. Richard
    Van Laethem, Kristel
    VIRUSES-BASEL, 2020, 12 (06):
  • [10] Portable Nanopore sequencing solution for next-generation HIV drug resistance testing
    Park, Sung Yong
    Faraci, Gina
    Ganesh, Kevin
    Dube, Michael P.
    Lee, Ha Youn
    JOURNAL OF CLINICAL VIROLOGY, 2024, 171